- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02882126
An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100020
- Beijing Chao-Yang Hospital
-
Beijing, China, 100029
- Beijing Anzhen Hospital, Capital Medical University
-
Beijing, China, 100032
- Peking Union Medical College Hospital
-
Beijing, China, 100038
- Beijing Shijitan Hospital
-
Beijing, China, 100037
- Fu Wai Hospital
-
Changsha, China, 410008
- Xiangya Hospital Centre South University
-
Guangzhou, China, 510080
- Guangdong General Hospital
-
Shanghai, China, 200433
- Shanghai Pulmonary Hospital
-
Shanghai, China, 200032
- Zhongshan Hospital affiliated with Fudan University
-
Wuhan, China, 430022
- Wuhan Asia Heart Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A subject is eligible for inclusion in this study if all of the following criteria apply:
- The subject voluntarily gives written informed consent to participate in the study.
- The subject participated in and completed study CVT-CV-003.
Sexually active women of childbearing potential must practice true abstinence from intercourse when it is in line with their preferred and usual lifestyle, or use two different forms of highly effective contraception. Medically acceptable forms of effective contraception include: (1) approved hormonal contraceptive (such as birth control pills), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, (3) an intrauterine device (IUD), or (4) partner vasectomy. Women of child bearing potential include any females who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or are not postmenopausal (defined as amenorrhea for at least 12 consecutive months).
Males participating in the study must use a condom during the length of the study, and for at least 48 hours after discontinuing study medication.
- The subject has not developed a concurrent illness or condition during the conduct of the previous study (including but not restricted to, sleep apnea, chronic renal insufficiency, anemia, uncontrolled systemic hypertension or left sided heart disease) that would make participation in this study detrimental to the subject's health in the opinion of the Investigator.
- In the opinion of the Principal Investigator, the subject is able to communicate effectively with study personnel, is considered reliable, willing and likely to be cooperative with protocol requirements, including attending all study visits, and is mentally and physically capable of administering Remodulin by continuous SC infusion using a micro infusion pump.
Exclusion Criteria:
A subject is not eligible for inclusion in this study if any of the following criteria apply:
- The subject permanently discontinued Remodulin during study CVT-CV-003.
- The subject is pregnant or lactating.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Subcutaneous Treprostinil
Open-label access; The initial dose of Remodulin for this study will be the same as each subject's final dose in study CVT-CV-003.
Dose modification will be based according to clinical response and tolerability.
|
Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events Among Subjects through Study Completion
Time Frame: Study Completion, an Average of 3 Years
|
Adverse events among participants will be recorded throughout participation in the study.
The incidence of adverse events among subjects through study completion, an average of 3 years, will be described by the number of subjects analyzed and the percentage of those subjects who experienced an adverse event until study completion.
|
Study Completion, an Average of 3 Years
|
Change in 6-minute Walk Distance (6MWD) From Baseline to Month 12
Time Frame: Baseline and Month 12
|
The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living.
Change in 6MWD from Baseline to Month 12, correlates with the current clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status.
Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for six minutes.
Distance <500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance >800 meters (with no rests) suggests mild or no limitation.
|
Baseline and Month 12
|
Change in Borg Dyspnea Score (following 6MWT) from Baseline to Month 12
Time Frame: Baseline and Month 12
|
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea (difficulty in breathing) experienced during the six-minute walk test (6MWT).
The Borg dyspnea score will be assessed immediately following the 6MWT.
Scores range from 0 (for no shortness of breath) to 10 (for the greatest shortness of breath ever experienced).
Changes from Baseline to Month 12 will be summarized and compared between treatment groups using descriptive statistics.
No formal hypothesis testing will be performed.
|
Baseline and Month 12
|
Number of Participants with a Change from Baseline World Health Organization (WHO) Functional Classification at Month 12
Time Frame: Change from Baseline at Month 12
|
The WHO Functional Class of pulmonary hypertension is a physical activity rating scale as follows: Class I: No limitation of physical activity.
Class II: Slight limitation of physical activity.
Class III: Marked limitation of physical activity.
Class IV: Inability to carry out any physical activity without symptoms.
Changes from Baseline to Month 12 will be summarized and compared between treatment groups using descriptive statistics.
No formal hypothesis testing will be performed.
|
Change from Baseline at Month 12
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CVT-CV-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Subcutaneous Treprostinil
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States
-
United TherapeuticsCVie Therapeutics Co. Ltd.WithdrawnPulmonary Arterial HypertensionChina
-
United TherapeuticsTerminatedPulmonary Hypertension Associated With HFpEFUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden
-
United TherapeuticsTerminatedPulmonary Hypertension | Heart Failure With Preserved Ejection FractionUnited States
-
United TherapeuticsEnrolling by invitationIdiopathic Pulmonary Fibrosis | Interstitial Lung DiseaseUnited States, Spain, Australia, Taiwan, Israel, Korea, Republic of, Argentina, Chile
-
United TherapeuticsActive, not recruitingPulmonary Arterial HypertensionUnited States
-
United TherapeuticsRecruitingIdiopathic Pulmonary Fibrosis | Interstitial Lung DiseaseTaiwan, Belgium, Spain, Korea, Republic of, Germany, Australia, Chile, Denmark, France, Mexico, Israel, Italy, Netherlands, Argentina, New Zealand, Peru
-
Insmed IncorporatedCompleted
-
United TherapeuticsCompletedPulmonary HypertensionUnited States, China, Israel, Belgium, Canada, France, India, Mexico, Austria, Italy, Netherlands, Poland, Puerto Rico